RCS - Ondine Biomedical - Microbiome research supports use of Steriwave

Ondine BiomedicalAnnouncement

31/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240131:nRSe4413Ba&default-theme=true

RNS Number : 4413B  Ondine Biomedical Inc.  31 January 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Microbiome research supports use of Steriwave

Ondine Biomedical demonstrated that photodisinfection does not harm the nasal
microbiome

Research presented by Canadian life sciences company, Ondine Biomedical Inc.
(LON:OBI), at the prestigious SPIE Photonics West
(https://spie.org/conferences-and-exhibitions/photonics-west#_=_) conference
in San Francisco, California shows that treatment with its Steriwave® Nasal
Photodisinfection System significantly reduces pathogens in the nose - a
reservoir for bacteria - yet does not produce long-term adverse effects on the
nasal microbiome. * 

Upon analysis of nasal swab samples, the research demonstrated an immediate
and highly significant (99.9+% ~3 log(10)) reduction in viable bacterial cells
and number of species, sustained for at least 24 hours. Importantly, within a
week, the microbiome rebounded to its original diversity and quantity. These
findings support Steriwave as an efficient, potent, short-acting, and
non-selective method of nasal decolonization, with the advantage of rapid
recovery of the native microbiome post-treatment.

In comparison to antibiotics, the study demonstrated that Steriwave is far
less likely to significantly alter the native microbiota. The antibiotic
mupirocin, commonly used for nasal decolonization, has been shown to affect
microbiota diversity for over 6 months, allowing disease-causing pathogens
like Staphylococcus aureus to colonize the nose before beneficial species,
putting patients at increased risk of infection. 1  Steriwave, in contrast,
offers a more favourable profile with the study results showing a reduced risk
of long-term microbiome disruption, as the microbiome consistently returns to
baseline.

Notably, minimizing microbiome disruption is also important in safeguarding
immune function, reducing vulnerability to infectious diseases by maintenance
of a microecological environment populated by beneficial commensal microbes
instead of disease-causing species. 2  The oral research presentation,
delivered by Ondine's Director of Research and Development, Dr. Caetano
Sabino, reported results from an exploratory study involving 35 healthy
volunteers, examining the responses of the nasal microbial population after
Steriwave treatment.

Organized by SPIE, the international society for optics and photonics, SPIE
Photonics West is the largest annual event for optic and photonic technologies
and one of the world's largest scientific conferences. Ondine's oral
presentation, titled "Microbiome Analysis of Photodynamic Nasal
Decolonization," was delivered at 10:20am on Tuesday 30 January, as part of
the "Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections
and Inflammatory Diseases" session.

 

**ENDS**

 

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                                           +001 (604) 665 0555

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam Butcher                      +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

About SPIE Photonics West

SPIE Photonics West is the optics and photonics industry's preeminent annual
conference and exhibition and is one of the largest scientific conferences in
the world. Its scope covers all areas regarding the use of light for
scientific and technological applications. The conference brings together tens
of thousands of researchers, innovators, engineers, and business leaders from
across the globe for an engaging week of research sharing, collaboration
forming, and innovation-inspiring exchanges. The week will include more than
4,500 technical presentations as well as showcasing over 1,200 companies in
three focused exhibitions.

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life science company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Ondine's nasal photodisinfection system has a CE mark
in Europe and the UK and is approved in Canada and several other countries
under the name Steriwave®. In the US, it has been granted Qualified
Infectious Disease Product designation and Fast Track status by the FDA and is
currently undergoing clinical trials for regulatory approval. Products beyond
nasal photodisinfection include therapies for a variety of medical indications
such as chronic sinusitis, ventilator-associated pneumonia, burns, and other
indications.

 

About Nasal Photodisinfection

Ondine's Steriwave® Nasal Photodisinfection System is a patented technology
using a proprietary light-activated antimicrobial (photosensitizer) to destroy
pathogens. The photodisinfection treatment is carried out by a trained
healthcare professional and is an easy to use, painless, two-step
process. The photosensitizer is applied to each nostril using a nasal swab,
followed by illumination of the area with a specific wavelength of red laser
light for less than five minutes. The light activates the photosensitizer,
causing an oxidative burst that is lethal to all types of pathogens. A key
benefit of this approach, unlike with antibiotics, is that pathogens do not
develop resistance to the therapy.

Nasal decolonization with antibiotics is already standard practice in many
hospitals prior to surgery, as pathogens in a patient's nasal cavities are a
major cause of surgical site infections (SSIs). Nasal decolonization is
recommended in the 2016 WHO Global guidelines for the prevention of surgical
site infections, 3  and the Society for Healthcare Epidemiology of America
(SHEA) guidelines, published in May 2023, recommend nasal decolonization for
major surgical procedures. 4  However, there is a growing need to reduce
antibiotic use and find non-antibiotic methods of nasal decolonization as
resistance rates have been reported as high as 81%. 5 

 

 *  The nasal microbiome consists of a complex community of microorganisms -
fungi, parasites, viruses, and bacteria - that can act in a symbiotic
relationship in the nasal cavity.

 1  Baede VO, Barray A, Tavakol M, Lina G, Vos MC, Rasigade JP. Nasal
microbiome disruption and recovery after mupirocin treatment in Staphylococcus
aureus carriers and noncarriers. Sci Rep. 2022 Nov 17;12(1):19738. doi:
10.1038/s41598-022-21453-4. PMID: 36396730; PMCID: PMC9671894.

 2  Cho I, Blaser MJ. The human microbiome: At the interface of health and
disease. Nat Rev Genet. 2012; 13: 260.

Arrieta M-C, Stiemsma LT, Amenyogbe N, Brown EM, Finlay B. The intestinal
microbiome in early life: Health and disease. Front Immunol. 2014; 5: 427.

DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of
dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016; 22:
1137-1150.

 3 
https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2

 4  Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent
surgical site infections in acute-care hospitals: 2022 Update. Infect Control
Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67

 5  Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical
implications and potential alternatives for the eradication of MRSA. J
Antimicrob Chemother. 2015;70(10):2681-2692. doi:10.1093/jac/dkv169

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKKBPKBKBBDN